J&J's ketamine-based nasal spray Spravato approved by US FDA to treat depression
The FDA approved Johnson & Johnson's Spravato, a ketamine-based nasal spray, to treat adults with major depressive disorder who have not responded to at least two oral antidepressants. This approval addresses the need for new options for treatment-resistant depression,
Respondents who said they used other drugs recreationally were also likelier to say they used ketamine during the past year ...
The following is a summary of “Intranasal racemic ketamine maintenance therapy for patients with treatment-resistant ...
A multidisciplinary approach, including ketamine withdrawal and symptom management, is essential to mitigate long-term ...
US Weekly on MSN5d
What Celebrities and Doctors Have Said About Ketamine Use: Chrissy Teigen, Matthew Perry, MoreCelebrities like Chrissy Teigen and Matthew Perry have been open about using ketamine for their mental health – here's what ...
Inquirer on MSN1d
Controlled drug Ketamine a lifeline for patients with severe depression in S’poreKetamine therapy is now a mainstream prescription for treatment-resistant depression. Read more at straitstimes.com.
IFLScience on MSN12d
Ketamine's Potential To Treat Depression Beautifully Shown In Struggling ZebrafishKetamine’s promising potential to ease depression is one of the reasons why its use has recently skyrocketed in the US and ...
Musk himself has said he uses the drug to treat depression, and he's frequently posted about it on X generally over the years ...
Johnson & Johnson (JNJ) stock in focus as FDA expands the label for its depression therapy Spravato (esketamine) allowing its ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback